USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Emerging Pharmaceuticals and Highly Potent Complex Molecules Creating Future Growth Potential
13-Sep-2021
North America
Market Research
PBE8-01-00-00-00
HC03449-NA-MT_25771
This study presents Frost & Sullivan’s overall market and segment-wise revenue forecasts of the global small molecule contract development and manufacturing organization (CDMO) industry. It highlights key growth opportunities for small molecule CDMOs based on the main evolution in their business models and strategic approaches as well as those of pharmaceutical sponsors. The study segments the market into two categories based on product type: Active pharmaceutical ingredients (API) manufacturing (API/drug substance) and finished dosage form (FDF) manufacturing (FDF/drug product). API is further segmented into innovator and generic APIs, while FDF is segmented into oral, semi-solid/liquid, and injectable forms. The market forecasts in this report are for 2020–2026, capturing key market developments such as capacity expansions, mergers, acquisitions, and expanding service offerings that are set to affect the overall small molecule CDMO market growth.
Other discussions in the study include:
• The impact of strategic imperatives on the industry
• Growth drivers and restraints
• Comprehensive insights on the competitive landscape
• Revenue share estimates of top market participants
• Strategic analysis of market developments in service offerings and business models
• Growth opportunities for small molecule CDMOs
Author: Surbhi Gupta
Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top Three Strategic Imperatives on the Global Small Molecule Contract Development and Manufacturing Organization (CDMO) Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Scope of Analysis
Market Segmentation by Product Type
Market Segmentation by Service Type
Key Competitors
Key Growth Metrics
Growth Drivers for the Small Molecule CDMO Market
Growth Restraints for the Small Molecule CDMO Market
Forecast Framework—Market Sizing
Forecast Methodology
Forecast Assumptions and Considerations
Revenue Forecast
Revenue Forecast Analysis
Revenue Forecast by Product Type
Revenue Forecast Analysis by Product Type
Revenue Forecast by Region
Revenue Forecast Analysis by Region
Major Reshoring Initiatives for Pharmaceutical Manufacturing
Revenue Split by Service Type
Revenue Split Analysis by Service Type
Competitive Environment
Market Share, Total Pharmaceutical CDMO Market
Small Molecule Market Outlook—Key Segment Share
Comparison between Small Molecules and Biologics Approvals
Expanding CDMO Value Chain—Comprehensive End-to-end Offering for Small Molecules and Biologics
CDMO Business Model Evolution—Transactional to Strategic Partnerships
Key Growth Trends Shaping the Small Molecule CDMO Industry
Key Consolidation and Expansion Steps in the Small Molecule CDMO Industry
Key Expansion Initiatives by Small Molecule CDMOs
Key Growth Metrics, Small Molecule CDMO Market—API
Revenue Forecast, Small Molecule CDMO Market—API
Revenue Forecast by Product Type, Small Molecule CDMO Market—API
Revenue Forecast Analysis by Product Type, Small Molecule CDMO Market—API
Key Growth Metrics, Small Molecule CDMO Market—FDF
Revenue Forecast, Small Molecule CDMO Market—FDF
Revenue Forecast by Product Type, Small Molecule CDMO Market—FDF
Revenue Forecast Analysis by Product Type, Small Molecule CDMO Market—FDF
Revenue Forecast Analysis by Product Type, Small Molecule CDMO Market—FDF (continued)
Growth Opportunity 1—Capacity Expansion in the US and Europe for Reshoring and Near-shoring Manufacturing
Growth Opportunity 1—Capacity Expansion in the US and Europe for Reshoring and Near-shoring Manufacturing (continued)
Growth Opportunity 2—Phase-appropriate Manufacturing Services for High-potency Drugs
Growth Opportunity 2—Phase-appropriate Manufacturing Services (continued)
Growth Opportunity 2—Phase-appropriate Manufacturing Services for High-potency Drugs (continued)
Growth Opportunity 3—Focus on Small/Emerging Biopharmaceutical Companies to Develop Innovative Small Molecules
Growth Opportunity 3—Focus on Small/Emerging Biopharmaceutical Companies to Develop Innovative Small Molecules (continued)
Growth Opportunity 4—Integrated Drug–Device Combination Products Services for New and Existing Drugs
Growth Opportunity 4—Integrated Drug–Device Combination Products Services for New and Existing Drugs (continued)
Your Next Steps
Why Frost, Why Now?
List of Exhibits
List of Exhibits (continued)
Legal Disclaimer
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Predecessor | MEF6 |
| Author | Surbhi Gupta |
| Industries | Healthcare |
| WIP Number | PBE8-01-00-00-00 |
| Is Prebook | No |
| GPS Codes | 9600-B1,9825-B1,9A06-B1,9571-B1,99BF-B1,99C0-B1,99C1-B1,99CB-B1,9568-B1,9611-B1 |
Global Small Molecule Contract Development and Manufacturing Organization (CDMO) Growth Opportunities
$4,950.00
Special Price $3,712.50 save 25 %